ALPS Group Inc(ALPS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.73 | Insider Own | 70.9% | Shs Outstand | 166.4M | Perf Week | -1.58% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 48.4M | Perf Month | -18.8% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | - | Inst Own | 0.32% | Short Float | 0.25% | Perf Quarter | -26.18% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 3.69% | Short Ratio | 2.14 | Perf Half Y | -65.37% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -17.24% | Short Interest | 0.12M | Perf YTD | -62.64% |
| Book/sh | -3.19 | P/C | 150.12 | EPS past 3/5Y | - -11.58% | ROE | -62.5% | 52W High | -97.3% ($12.01) | Perf Year | -97.3% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 41.68% ($0.23) | Perf 3Y | -96.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -610.86% | Gross Margin | - | Volatility(W/M) | 2.11% 4.74% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | 2023/2/13 | Quick Ratio | 0.04 | EPS Q/Q | -1113.92% | Profit Margin | - | RSI (14) | 28.84 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.04 | Sales Q/Q | - | SMA20 | -8.43% ($0.35) | Beta | -0.53 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/7 | SMA50 | -11.57% ($0.36) | Rel Volume | 0.64 | Prev Close | $0.33 |
| Employees | 89 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -52.88% ($0.68) | Avg Volume(3M) | 0.06M | Price | $0.32 |
| IPO | 2021/12/23 | Option/Short | No/Yes | Trades | 74 | Volume | 35,443 | Change | -0.85% |
🧬 Alps Group is a healthcare company that has integrated research and development, medical services, and wellness solutions into a single ecosystem. Its goal is to make predictive, preventive, and precision medicine more accessible and affordable, and through its subsidiary Alps Life Sciences, it pursues an integrated healthcare model centered on advanced therapeutics.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
ALPS has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -97.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #409 of 594 in the industry
Based on market cap of $54M.
FAQ
What kind of company is ALPS?
ALPS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALPS?
The market cap of ALPS is approximately $54M, ranking 4,812 within its sector.
What is the 52-week high and low for ALPS?
ALPS has recorded a 52-week high of $12.01 and a low of $0.23.
